No Data
No Data
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Bluebird Bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking
Bluebird Bio Trading Halted, News Pending
tian liang : This is a big guy
Buzz light year : great summary
104209762 : Thank you
103880589 : The ideas are similar, but the market situation is still hard to figure out. It still depends on what kind of chess the dealer wants to play. I am still not very familiar with operating the stock market. I am more proficient in Bitcoin.
70183993 : market will go up on first year when new president in office then drop on second years, look at the record, Obama,Trump 1.0 Biden .
View more comments...